1887

Abstract

Arbidol (, also known as umifenovir) is used clinically in several countries as an anti-influenza virus drug. inhibits multiple enveloped viruses and the primary mode of action is inhibition of virus entry and/or fusion of viral membranes with intracellular endosomal membranes. is also an effective inhibitor of non-enveloped poliovirus types 1 and 3. In the current report, we evaluate the antiviral potential of against another picornavirus, foot-and-mouth disease virus (FMDV), a member of the genus and an important veterinary pathogen. inhibits the replication of FMDV RNA sub-genomic replicons. inhibition of FMDV RNA replication is not a result of generalized inhibition of cellular uptake of cargo, such as transfected DNA, and can be added to cells up to 3 h post-transfection of FMDV RNA replicons and still inhibit FMDV replication. prevents the recovery of FMDV replication upon withdrawal of the replication inhibitor guanidine hydrochloride (GuHCl). Although restoration of FMDV replication is known to require protein synthesis upon GuHCl removal, does not suppress cellular translation or FMDV internal ribosome entry site (IRES)-driven translation. also inhibits infection with the related equine rhinitis A virus (ERAV). Collectively, the data demonstrate that can inhibit some non-enveloped picornaviruses. The data are consistent with inhibition of picornavirus genome replication, possibly via the disruption of intracellular membranes on which replication complexes are located.

Keyword(s): antiviral , arbidol , ERAV , FMDV , indole and picornavirus
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001283
2019-09-01
2019-09-18
Loading full text...

Full text loading...

/deliver/fulltext/jgv/100/9/1293.html?itemId=/content/journal/jgv/10.1099/jgv.0.001283&mimeType=html&fmt=ahah

References

  1. Fields BN, Knipe DM, Howley PM. Fields virology , 6th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2013
    [Google Scholar]
  2. Jamal SM, Belsham GJ. Foot-and-mouth disease: past, present and future. Vet Res 2013;44:116 [CrossRef]
    [Google Scholar]
  3. Souley Kouato B, De Clercq K, Abatih E, Dal Pozzo F, King DP et al. Review of epidemiological risk models for foot-and-mouth disease: implications for prevention strategies with a focus on Africa. PLoS One 2018;13:e0208296 [CrossRef]
    [Google Scholar]
  4. Thompson D, Muriel P, Russell D, Osborne P, Bromley A et al. Economic costs of the foot and mouth disease outbreak in the United Kingdom in 2001. Rev Sci Tech 2002;21:675–687 [CrossRef]
    [Google Scholar]
  5. Knight-Jones TJ, Rushton J. The economic impacts of foot and mouth disease – what are they, how big are they and where do they occur?. Prev Vet Med 2013;112:161–173 [CrossRef]
    [Google Scholar]
  6. Alexandersen S, Zhang Z, Donaldson AI. Aspects of the persistence of foot-and-mouth disease virus in animals—the carrier problem. Microbes Infect 2002;4:1099–1110 [CrossRef]
    [Google Scholar]
  7. Tulloch F, Pathania U, Luke GA, Nicholson J, Stonehouse NJ et al. FMDV replicons encoding green fluorescent protein are replication competent. J Virol Methods 2014;209:35–40 [CrossRef]
    [Google Scholar]
  8. Herod MR, Loundras EA, Ward JC, Tulloch F, Rowlands DJ et al. Employing transposon mutagenesis to investigate foot-and-mouth disease virus replication. J Gen Virol 2015;96:3507–3518 [CrossRef]
    [Google Scholar]
  9. Romero-Brey I, Bartenschlager R. Membranous replication factories induced by plus-strand RNA viruses. Viruses 2014;6:2826–2857 [CrossRef]
    [Google Scholar]
  10. Blaising J, Polyak SJ, Pécheur EI. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res 2014;107:84–94 [CrossRef]
    [Google Scholar]
  11. Leneva IA, Fediakina IT, Gus'kova TA, Glushkov RG. [Sensitivity of various influenza virus strains to arbidol. Influence of arbidol combination with different antiviral drugs on reproduction of influenza virus A]. Ter Arkh 2005;77:84–88
    [Google Scholar]
  12. Shi L, Xiong H, He J, Deng H, Li Q et al. Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. Arch Virol 2007;152:1447–1455 [CrossRef]
    [Google Scholar]
  13. Deng HY, Luo F, Shi LQ, Zhong Q, Liu YJ et al. Efficacy of arbidol on lethal hantaan virus infections in suckling mice and in vitro. Acta Pharmacol Sin 2009;30:1015–1024 [CrossRef]
    [Google Scholar]
  14. Blaising J, Lévy PL, Polyak SJ, Stanifer M, Boulant S et al. Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking. Antiviral Res 2013;100:215–219 [CrossRef]
    [Google Scholar]
  15. Delogu I, Pastorino B, Baronti C, Nougairède A, Bonnet E et al. In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant. Antiviral Res 2011;90:99–107 [CrossRef]
    [Google Scholar]
  16. Zhao C, Zhao Y, Chai H, Gong P. Synthesis and in vitro anti-hepatitis B virus activities of some ethyl 5-hydroxy-1H-indole-3-carboxylates. Bioorg Med Chem 2006;14:2552–2558 [CrossRef]
    [Google Scholar]
  17. Boriskin YS, Leneva IA, Pecheur EI, Polyak SJ. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem 2008;15:997–1005 [CrossRef]
    [Google Scholar]
  18. Boriskin YS, Pécheur EI, Polyak SJ. Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection. Virol J 2006;3:56 [CrossRef]
    [Google Scholar]
  19. Pécheur EI, Lavillette D, Alcaras F, Molle J, Boriskin YS et al. Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol. Biochemistry 2007;46:6050–6059 [CrossRef]
    [Google Scholar]
  20. Teissier E, Zandomeneghi G, Loquet A, Lavillette D, Lavergne JP et al. Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol. PLoS One 2011;6:e15874 [CrossRef]
    [Google Scholar]
  21. Pécheur EI, Borisevich V, Halfmann P, Morrey JD, Smee DF et al. The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses. J Virol 2016;90:3086–3092 [CrossRef]
    [Google Scholar]
  22. Hulseberg CE, Fénéant L, Szymańska-de Wijs KM, Kessler NP, Nelson EA et al. Arbidol and other low-molecular-weight drugs that inhibit Lassa and Ebola viruses. J Virol in press 2019;93: [CrossRef]
    [Google Scholar]
  23. Fink SL, Vojtech L, Wagoner J, Slivinski NSJ, Jackson KJ et al. The antiviral drug arbidol inhibits Zika virus. Sci Rep 2018;8:8989 [CrossRef]
    [Google Scholar]
  24. Haviernik J, Štefánik M, Fojtíková M, Kali S, Tordo N et al. Arbidol (Umifenovir): a broad-spectrum antiviral drug that inhibits medically important arthropod-borne flaviviruses. Viruses 2018;10:184 [CrossRef]
    [Google Scholar]
  25. Brooks MJ, Burtseva EI, Ellery PJ, Marsh GA, Lew AM et al. Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions. J Med Virol 2012;84:170–181 [CrossRef]
    [Google Scholar]
  26. Cho MW, Ehrenfeld E. Rapid completion of the replication cycle of hepatitis A virus subsequent to reversal of guanidine inhibition. Virology 1991;180:770–780 [CrossRef]
    [Google Scholar]
  27. Barton DJ, Black EP, Flanegan JB. Complete replication of poliovirus in vitro: preinitiation RNA replication complexes require soluble cellular factors for the synthesis of VPg-linked RNA. J Virol 1995;69:5516–5527
    [Google Scholar]
  28. Barton DJ, Flanegan JB. Synchronous replication of poliovirus RNA: initiation of negative-strand RNA synthesis requires the guanidine-inhibited activity of protein 2C. J Virol 1997;71:8482–8489
    [Google Scholar]
  29. Belsham GJ, Normann P. Dynamics of picornavirus RNA replication within infected cells. J Gen Virol 2008;89:485–493 [CrossRef]
    [Google Scholar]
  30. Kadam RU, Wilson IA. Structural basis of influenza virus fusion inhibition by the antiviral drug arbidol. Proc Natl Acad Sci USA 2017;114:206–214 [CrossRef]
    [Google Scholar]
  31. Martínez-Salas E, Francisco-Velilla R, Fernandez-Chamorro J, Lozano G, Diaz-Toledano R. Picornavirus IRES elements: RNA structure and host protein interactions. Virus Res 2015;206:62–73 [CrossRef]
    [Google Scholar]
  32. Daijogo S, Semler BL. Mechanistic intersections between picornavirus translation and RNA replication. Adv Virus Res 2011;80:1–24 [CrossRef]
    [Google Scholar]
  33. Stewart H, Walter C, Jones D, Lyons S, Simmonds P et al. The non-primate hepacivirus 5' untranslated region possesses internal ribosomal entry site activity. J Gen Virol 2013;94:2657–2663 [CrossRef]
    [Google Scholar]
  34. Licursi M, Christian SL, Pongnopparat T, Hirasawa K. In vitro and in vivo comparison of viral and cellular internal ribosome entry sites for bicistronic vector expression. Gene Ther 2011;18:631–636 [CrossRef]
    [Google Scholar]
  35. Loundras EA, Herod MR, Harris M, Stonehouse NJ. Foot-and-mouth disease virus genome replication is unaffected by inhibition of type III phosphatidylinositol-4-kinases. J Gen Virol 2016;97:2221–2230 [CrossRef]
    [Google Scholar]
  36. Gunnery S, Mäivali U, Mathews MB. Translation of an uncapped mRNA involves scanning. J Biol Chem 1997;272:21642–21646 [CrossRef]
    [Google Scholar]
  37. Belov GA. Dynamic lipid landscape of picornavirus replication organelles. Curr Opin Virol 2016;19:1–6 [CrossRef]
    [Google Scholar]
  38. Gorbalenya AE, Koonin EV, Donchenko AP, Blinov VM. A conserved NTP-motif in putative helicases. Nature 1988;333:22 [CrossRef]
    [Google Scholar]
  39. Bienz K, Egger D, Troxler M, Pasamontes L. Structural organization of poliovirus RNA replication is mediated by viral proteins of the P2 genomic region. J Virol 1990;64:1156–1163
    [Google Scholar]
  40. Pincus SE, Diamond DC, Emini EA, Wimmer E. Guanidine-selected mutants of poliovirus: mapping of point mutations to polypeptide 2C. J Virol 1986;57:638–646
    [Google Scholar]
  41. Egger D, Bienz K. Intracellular location and translocation of silent and active poliovirus replication complexes. J Gen Virol 2005;86:707–718 [CrossRef]
    [Google Scholar]
  42. Bienz K, Egger D, Rasser Y, Bossart W. Kinetics and location of poliovirus macromolecular synthesis in correlation to virus-induced cytopathology. Virology 1980;100:390–399 [CrossRef]
    [Google Scholar]
  43. Brooks MJ, Sasadeusz JJ, Tannock GA. Antiviral chemotherapeutic agents against respiratory viruses: where are we now and what's in the pipeline?. Curr Opin Pulm Med 2004;10:197–203
    [Google Scholar]
  44. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 2005;102:9294–9299 [CrossRef]
    [Google Scholar]
  45. Nakabayashi H, Taketa K, Yamane T, Miyazaki M, Miyano K et al. Phenotypical stability of a human hepatoma cell line, HuH-7, in long-term culture with chemically defined medium. Gan 1984;75:151–158
    [Google Scholar]
  46. Simizu B, Rhim JS, Wiebenga NH. Characterization of the Tacaribe group of arboviruses. 1. propagation and plaque assay of Tacaribe virus in a line of African green monkey kidney cells (Vero). Exp Biol Med 1967;125:119–123 [CrossRef]
    [Google Scholar]
  47. Macpherson I, Stoker M. Polyoma transformation of hamster cell clones—an investigation of genetic factors affecting cell competence. Virology 1962;16:147–151 [CrossRef]
    [Google Scholar]
  48. Polyak SJ, Morishima C, Lohmann V, Pal S, Lee DY et al. Identification of hepatoprotective flavonolignans from silymarin. Proc Natl Acad Sci USA 2010;107:5995–5999 [CrossRef]
    [Google Scholar]
  49. Herod MR, Gold S, Lasecka-Dykes L, Wright C, Ward JC et al. Genetic economy in picornaviruses: foot-and-mouth disease virus replication exploits alternative precursor cleavage pathways. PLoS Pathog 2017;13:e1006666 [CrossRef]
    [Google Scholar]
  50. Herod MR, Ferrer-Orta C, Loundras EA, Ward JC, Verdaguer N et al. Both cis and trans activities of foot-and-mouth disease virus 3D polymerase are essential for viral RNA replication. J Virol 2016;90:6864–6883 [CrossRef]
    [Google Scholar]
  51. Tuthill TJ, Harlos K, Walter TS, Knowles NJ, Groppelli E et al. Equine rhinitis A virus and its low pH empty particle: clues towards an aphthovirus entry mechanism?. PLoS Pathog 2009;5:e1000620 [CrossRef]
    [Google Scholar]
  52. Baer A, Kehn-Hall K. Viral concentration determination through plaque assays: using traditional and novel overlay systems. J Vis Exp 2014;93:e52065
    [Google Scholar]
  53. Lindenbach BD. Measuring HCV infectivity produced in cell culture and in vivo. Methods Mol Biol 2009;510:329–336
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001283
Loading
/content/journal/jgv/10.1099/jgv.0.001283
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error